Cronos Group Inc. (CRON)
Cronos: Geographic Expansion Backed By A Strong Balance Sheet
Cronos remains a Strong Buy, supported by robust fundamentals, international expansion, and a depressed $1B valuation with $784M in cash. CRON's acquisition of CanAdelaar and expansion into Europe and Australia position it for accelerated growth and margin improvement over the next 24-36 months. GrowCo's completed capacity expansion and 70% flower volume increase in 2026 are expected to drive top-line and EBITDA margin gains.
3 Canadian Marijuana Stocks Today's Stock Market That Could Soon Run
The cannabis industry is in another pivotal time where consistent changes are being made. Laws and regulations have been passed across the country that have aided in the further development of industry. For most marijuana stock investors, this is the area where shareholders tend to focus. Investors know that a company is doing well, or is working towards a significant goal, which can all lead to profitability. There are different sectors and markets to pay attention to.
Eni's Cronos Development May Add New Gas Volumes to Europe From 2027
E considers moving ahead with the Cronos gas project off Cyprus, which could supply natural gas to Europe by 2027.
Riding the Marijuana Reclassification Wave: 3 Stocks to Watch in 2026
Marijuana's potential move to Schedule III could reshape cannabis economics, putting CRON, VFF and TLRY in focus for 2026 investors.
Cronos: A Standout Balance Sheet Among Its Peers
Cronos Group operates in a highly competitive industry but has a marked advantage over its peers owing to its vastly superior balance sheet. This superiority is a result of a 2019 investment by Altria of $1.8 billion. CRON has experienced consistent cash burn and deep losses since 2019 as it has built and adapted its operations to the newly legalized adult-use cannabis industry in Canada.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Cronos Group Plans Strategic Europe Expansion: How to Play the Stock?
CRON's planned CanAdelaar acquisition boosts its push into the Dutch adult-use cannabis market and highlights its strengthening international momentum.
Cronos Just Bought Europe's Top Cannabis Producer — Is This the Catalyst Investors Have Waited 5 Years For?
For years, North American cannabis investors have endured a brutal hangover.
Congressional hemp restrictions threaten $28 billion industry, sending companies scrambling
The congressional funding bill included a THC cap that effectively bans most hemp products, a move industry leaders say threatens the $28 billion market. More than 300,000 jobs are at risk, with economic impacts expected in states with large hemp sectors, including Kentucky, Texas and Utah, industry experts said.
Bitcoin, Ethereum, XRP, Cronos Gain. 2 Ways Trump Is Boosting Cryptos.
Bitcoin, Ethereum and other cryptocurrencies were reacting to hopes of interest-rate cuts while President Donald Trump's family is backing smaller crypto Cronos.
Cronos Rallies Amidst Greater Cannabis Sector Rally Over Possible Rescheduling
Cannabis stocks rallied today over news of possible rescheduling by the Trump administration. Even though Cronos Group Inc. does not have a U.S. entry strategy, its stock price was up 15% on the news. Cronos reported improved financial performance last Thursday with higher revenues and improved international sales.
Cronos Group Inc. (CRON) Q2 2025 Earnings Call Transcript
Cronos Group Inc. (NASDAQ:CRON ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Anna Shlimak - Chief Financial Officer Harrison Aaron - Corporate Participant Michael Ryan Gorenstein - President, CEO & Chairman Operator Good morning. My name is Stephen, and I will be your conference operator today.
